Sientra (SIEN) Earns Daily News Sentiment Score of -0.10
News articles about Sientra (NASDAQ:SIEN) have been trending somewhat negative this week, Alpha One Sentiment reports. The research firm, a service of Accern, identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sientra earned a coverage optimism score of -0.10 on Alpha One’s scale. Alpha One also assigned media stories about the medical instruments supplier an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media stories that may have effected AlphaOne Sentiment Analysis’s analysis:
- Sientra Inc (SIEN) Research Coverage Started at Lake Street Capital (americanbankingnews.com)
- Breast Implant Market Research Report : : Brand Analysis and Forecast upto 2025 (medgadget.com)
- Breast Implant Market to Reach US $1,482.1 Mn by 2024 (sbwire.com)
- Breast Implants Market in APAC to Reach US$ 287.0 Mn by 2025 (sbwire.com)
- Sientra (SIEN) Receives Daily News Impact Score of -0.12 (americanbankingnews.com)
SIEN has been the topic of a number of analyst reports. Zacks Investment Research downgraded Sientra from a “hold” rating to a “sell” rating in a research report on Thursday, January 5th. Lake Street Capital initiated coverage on Sientra in a research report on Monday. They set a “buy” rating and a $11.00 price target on the stock.
Shares of Sientra (NASDAQ:SIEN) traded down 1.57% during midday trading on Tuesday, reaching $8.13. The company had a trading volume of 114,756 shares. Sientra has a one year low of $5.60 and a one year high of $10.37. The company has a 50 day moving average price of $8.84 and a 200-day moving average price of $8.54. The firm’s market capitalization is $153.11 million.
Sientra (NASDAQ:SIEN) last posted its earnings results on Tuesday, March 14th. The medical instruments supplier reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.09. Sientra had a negative net margin of 382.33% and a negative return on equity of 44.19%. The firm had revenue of $6.50 million for the quarter, compared to analysts’ expectations of $6.76 million. The business’s quarterly revenue was up 333.3% on a year-over-year basis. On average, analysts anticipate that Sientra will post ($1.99) EPS for the current fiscal year.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc and related companies with MarketBeat.com's FREE daily email newsletter.